✦ LIBER ✦

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

Book ID: 122608282
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 149 KB
Volume: 12
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(95)98955-A

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of irinotecan and cisplati

Phase I study of irinotecan and cisplatin with granulocyte colony- stimulating factor support for advanced non-small-cell lung cancer

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A phase II study of irinotecan and infus

A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

✍ Kiyoshi Mori; Suguru Machida; Takeshi Yoshida; Munehide Yoshida; Yasuliko Kano; 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 68 KB

A phase I study of irinotecan and infusi

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer

✍ K. Mori; T. Hirose; S. Machida; K. Yokoyama; K. Tominaga 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 275 KB

A phase II study of irinotecan and infus

A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor (rG-CSF) support for advanced non-small cell lung cancer (NSCLC)

✍ Mori, K.; Machida, S.; Yoshida, T.; Noda, M.; Tominaga, K. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Phase I/II study of carboplatin and oral

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer

✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-

Phase III study of carboplatin and oral

Phase III study of carboplatin and oral etoposide with granulocyte- colony stimulating factor in advanced nonsmall cell lung cancer

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 137 KB